[1] Magaz M, Baiges A, Hernández-Gea V, Precision medicine in variceal bleeding: Are we there yet? J Hepatol, 2020, 72: 774-784.
[2] Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology, 2004, 39: 280-282.
[3] Berzigotti A, Seijo S, Reverter E, et al. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol, 2013, 7: 141-155.
[4] D’Amico G, Morabito A, D’Amico M, et al. Clinical states of cirrhosis and competing risks. J Hepatol, 2018, 68: 563-576.
[5] Garcia-Tsao G, Friedman S, Iredale J, et al. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology, 2010, 51: 1445-1449.
[6] Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology, 2007, 46: 922-938.
[7] Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology, 2013, 144: 102-111.
[8] Friedrich-Rust M, Poynard T, Castera L, Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastro Hepat, 2016, 13: 402-411.
[9] Sandahl TD, McGrail R, Møller HJ, et al. The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis. Aliment Pharmacol Ther, 2016, 43: 1222-1231.
[10] Mihos CG, Pineda AM, Santana O. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res, 2014, 88: 12-19.
[11] Post AB. Beta-blockers to prevent gastroesophageal varices in cirrhosis. N Engl J Med, 2006, 354: 1318-1320.
[12] Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol, 2003, 38: 266-272.
[13] Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2019, 393: 1597-1608.
[14] Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med, 2005, 353: 2254-2261.
[15] Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated Cirrhosis. Gastroenterology, 2016, 150: 430-440.
[16] Sharma M, Singh S, Desai V, et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis. Hepatology, 2019, 69: 1657-1675.
[17] Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut, 2013, 62: 1634-1641.
[18] Sarin SK, Wadhawan M, Agarwal SR, et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol, 2005, 100: 797-804.
[19] Reiberger T, Püspök A, Schoder M, et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr, 2017, 129: 135-158.
[20] Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med, 2013, 368: 11-21.
[21] Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology, 2017, 65: 310-335.
[22] Garcia-Tsao G, Lim JK, Lim J, et al. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol, 2009, 104: 1802-1829.
[23] Villanueva C, Graupera I, Aracil C, et al. A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis. Hepatology, 2017, 65: 1693-1707. |
